Nanion Corporate Blog

 

10.09.2019: Press Release - Launch of the FLEXcyte 96

Launch of the FLEXcyte 96 – pushing the boundaries of cardiac safety screening.

Nanion Technologies is proud to announce the launch of the FLEXcyte 96 technology for cardiac contraction force measurements. Improving patient safety and reducing animal tests while saving time and money by replacing unnecessary in vivo experiments is the aim of this novel assay technology.

The FLEXcyte 96 has been developed in cooperation with innoVitro GmbH. Read the full press release here

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok